Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.21.1
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of warrant and stock option grants with time-based vesting
    Warrant Grants     Stock Option Grants     Restricted
Stock Units		  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2020     672,459     $ 8.09       118,388     $ 3.25       2,301,053  
Granted     90,461       4.00           -                   -           -  
Exercised     -       -       -       -       (8,832 )
Expired     -       -       -       -       (64,583 )
Balance at March 31, 2021     762,920     $ 7.60       118,388     $ 3.25       2,227,638  
Exercisable at March 31, 2021     762,920     $ 7.60       118,388     $ 3.25       2,227,638  
Schedule of fair value of the warrants as of original issuance date
    Issuance date  
Risk-free interest rate     0.49 %
Expected dividend yield     - %
Expected volatility     100 %
Term     5 years
Fair value of common stock   $ 1.95
Schedule of company’s outstanding warrants and options
Warrants Outstanding     Warrants Exercisable  
Exercise Price Range     Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		     Weighted Average
Exercise Price		     Number
Exercisable		     Weighted Average
Exercise Price		     Intrinsic Value  
$ 3.80 - $141.17       762,920       3.04     $ 7.60       762,920     $ 7.60                  -  
Options Outstanding     Options Exercisable  
Exercise Price Range     Number
Outstanding		     Weighted Average Remaining
Contractual Life
(in years)		     Weighted Average
Exercise Price		     Number
Exercisable		     Weighted Average
Exercise Price		     Intrinsic Value  
$ 2.64 - $28.50       118,388       3.36     $ 3.25       118,388     $ 3.25               -  
Schedule of stock-based compensation expense
    For the three months ended  
    March 31,  
    2021     2020  
Stock-based compensation expense   $ 500,718     $ 367,600  
Schedule of stock-based compensation expense categorized by equity components
    For the three months ended  
    March 31,  
    2021     2020  
Common stock   $ 500,718     $ 367,600  
Total   $ 500,718     $ 367,600